Overview

  • Product name
    Anti-BAFF Receptor antibody [11C1]
    See all BAFF Receptor primary antibodies
  • Description
    Mouse monoclonal [11C1] to BAFF Receptor
  • Tested applications
    Suitable for: IHC-P, Flow Cyt, IHC-Frmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Tissue/ cell preparation (Human) - human BAFF Receptor transfected mouse B cell lymphoma L1.2 cells.

  • Positive control
    • IHC-P: human tonsil FACS: CD19+ B cells from tonsil.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Concentration information loading...
  • Purity
    Protein G purified
  • Clonality
    Monoclonal
  • Clone number
    11C1
  • Myeloma
    Sp2/0
  • Isotype
    IgG1
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab16232 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
Flow Cyt
IHC-Fr
  • Application notes
    Flow Cyt: Use at an assay dependent dilution.
    IHC-Fr: Use at an assay dependent dilution.
    IHC-P: Use at an assay dependent dilution. Antigen retrieval with EDTA based solution (pH9.0) and heat.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.
    • Tissue specificity
      Highly expressed in spleen and lymph node, and in resting B-cells. Detected at lower levels in activated B-cells, resting CD4+ T-cells, in thymus and peripheral blood leukocytes.
    • Involvement in disease
      Defects in TNFRSF13C are the cause of immunodeficiency common variable type 4 (CVID4) [MIM:613494]; also called antibody deficiency due to BAFFR defect. CVID4 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    • Sequence similarities
      Contains 1 TNFR-Cys repeat.
    • Cellular localization
      Membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • B cell activating factor receptor antibody
      • B-cell-activating factor receptor antibody
      • BAFF R antibody
      • BAFF receptor antibody
      • BAFF-R antibody
      • BAFFR antibody
      • BLyS receptor 3 antibody
      • BlySR3 antibody
      • BR 3 antibody
      • BR3 antibody
      • BROMIX antibody
      • CD 268 antibody
      • CD268 antibody
      • CD268 antigen antibody
      • CVID4 antibody
      • MGC138235 antibody
      • OTTHUMP00000028746 antibody
      • Prolixin antibody
      • TNFRSF 13C antibody
      • Tnfrsf13c antibody
      • TR13C_HUMAN antibody
      • Tumor necrosis factor receptor subunit member 13C antibody
      • Tumor necrosis factor receptor superfamily member 13C antibody
      see all

    Anti-BAFF Receptor antibody [11C1] images

    • Immunohistochemistry staining of human tonsil with ab16232, showing intense staining of B cell follicles and weaker staining on GC. Magnification X200.
    • FACS analysis of B cells performed by gating on CD19+ B cells from tonsil.

    References for Anti-BAFF Receptor antibody [11C1] (ab16232)

    This product has been referenced in:
    • Chong BF  et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci N/A:N/A (2013). Human . Read more (PubMed: 24315762) »
    • Di Carlo E  et al. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 15:2979-87 (2009). IHC-P ; Human . Read more (PubMed: 19366834) »

    See all 4 Publications for this product

    Product Wall

    According to our records, ab16081 and ab16232 was proving difficult to use when staining spleen and aorta tissues presumably in immunohistochemistry and we were in contact in order to help resolve the issue.
    Looking at our correspondence, it appea...

    Read More

    I am sorry to hear that you have experienced difficulties with two of our products in the past. However, because we carry over 90,000 products, it isn't feasible for us to keep small sample sizes of our products.
    We are happy to reassure our custo...

    Read More

    Thank you for your reply.

    I am sorry that the vials you received did not contain the full amount of the product and I apologize for the inconvenience. As requested, I have issued a free of charge replacement vials of ab16081 and ab16232 with...

    Read More

    I'm afraid the the epitope for ab16232 has not been mapped. Sorry I couldn't help you more on this occasion,

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up